Deutsche Bank Aktiengesellschaft Reaffirms Sell Rating for AstraZeneca (LON:AZN)

AstraZeneca (LON:AZN)‘s stock had its “sell” rating restated by research analysts at Deutsche Bank Aktiengesellschaft in a research report issued to clients and investors on Wednesday, Digital Look reports. They presently have a £115 price target on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft’s price target points to a potential downside of 3.72% from the stock’s previous close.

A number of other research firms have also issued reports on AZN. Citigroup increased their price target on AstraZeneca from £175 to £178 and gave the company a “buy” rating in a research report on Tuesday, July 28th. Jefferies Financial Group reissued a “buy” rating and set a £175 price objective on shares of AstraZeneca in a research report on Monday, August 3rd. Finally, Berenberg Bank restated a “buy” rating and set a £160 target price on shares of AstraZeneca in a research note on Tuesday, July 28th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of £152.17.

AstraZeneca Trading Down 0.2%

LON:AZN opened at £119.44 on Wednesday. AstraZeneca has a 12-month low of £107.84 and a 12-month high of £157.32. The firm has a market cap of £185.24 billion, a PE ratio of 17.88, a price-to-earnings-growth ratio of 0.86 and a beta of 0.21. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 64.10. The stock has a fifty day moving average price of £126.87 and a 200 day moving average price of £137.23.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.